Compare Inovio Pharmaceuticals Inc (INO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SGOV | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Fixed Income |
52-Week High | $2.87 | $100.74 |
52-Week Low | $0.66 | $100.28 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% with a bearish technical signal from moving averages. It offers a defensive cash alternative, highlighted by recent institutional stake changes and a focus on ultra-short Treasury exposure amid market volatility. The ETF provides monthly distributions, with recent dividends around $0.30 per share.
The outlook remains stable as a low-risk income vehicle, benefiting from rising yields and investor defensive pivots. Key risks include interest rate fluctuations and macroeconomic shifts, but its principal protection and liquidity appeal to cautious investors seeking yield above traditional savings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
